PE20120909A1 - Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usos de la misma - Google Patents

Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usos de la misma

Info

Publication number
PE20120909A1
PE20120909A1 PE2011001988A PE2011001988A PE20120909A1 PE 20120909 A1 PE20120909 A1 PE 20120909A1 PE 2011001988 A PE2011001988 A PE 2011001988A PE 2011001988 A PE2011001988 A PE 2011001988A PE 20120909 A1 PE20120909 A1 PE 20120909A1
Authority
PE
Peru
Prior art keywords
mycoplasma hyopneumoniae
strain
sensitive
temperature
same
Prior art date
Application number
PE2011001988A
Other languages
English (en)
Spanish (es)
Inventor
Rima Youil
El-Osta Youssef Abs
Glenn Browning
Phillip Markham
Original Assignee
Bioproperties Pty Ltd
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009902255A external-priority patent/AU2009902255A0/en
Application filed by Bioproperties Pty Ltd, Univ Melbourne filed Critical Bioproperties Pty Ltd
Publication of PE20120909A1 publication Critical patent/PE20120909A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0241Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36Adaptation or attenuation of cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35Mycoplasma
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/87Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PE2011001988A 2009-05-19 2010-05-19 Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usos de la misma PE20120909A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2009902255A AU2009902255A0 (en) 2009-05-19 Bacterial strain, vaccine and uses thereof

Publications (1)

Publication Number Publication Date
PE20120909A1 true PE20120909A1 (es) 2012-08-19

Family

ID=43125658

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001988A PE20120909A1 (es) 2009-05-19 2010-05-19 Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usos de la misma

Country Status (17)

Country Link
US (1) US8524252B2 (https=)
EP (1) EP2453913B1 (https=)
JP (1) JP5744852B2 (https=)
KR (1) KR101734590B1 (https=)
CN (1) CN102458462B (https=)
AU (1) AU2010251761B2 (https=)
BR (1) BRPI1010679B1 (https=)
CA (1) CA2762587C (https=)
CL (1) CL2011002923A1 (https=)
DK (1) DK2453913T3 (https=)
EA (1) EA021102B1 (https=)
ES (1) ES2579935T3 (https=)
MX (1) MX2011012362A (https=)
NZ (1) NZ596722A (https=)
PE (1) PE20120909A1 (https=)
WO (1) WO2010132932A1 (https=)
ZA (1) ZA201109185B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013526866A (ja) * 2010-05-19 2013-06-27 バイオプロパティーズ ピーティーワイ リミテッド 弱毒化マイコプラズマに関する方法
EP2684959A1 (en) * 2012-07-10 2014-01-15 Laboratorios Hipra, S.A. Vectors for transforming Mycoplasma hyopneumoniae, transformed M.hyopneumoniae strains, and use thereof
CN104685057B (zh) * 2012-07-10 2019-04-16 海博莱科学有限公司 用于转化猪肺炎支原体的载体,转化的猪肺炎支原体菌株及其用途
AU2013370982C9 (en) 2012-12-28 2019-01-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
MX361273B (es) 2012-12-28 2018-12-03 Boehringer Ingelheim Vetmedica Gmbh Metodo para obtener una vacuna de mycoplasma.
EP2913947B1 (en) * 2014-02-27 2019-11-27 ADVA Optical Networking SE Passive optical network and optical line terminal
KR20160099223A (ko) * 2015-02-12 2016-08-22 강원대학교산학협력단 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법
US10071149B2 (en) 2016-05-03 2018-09-11 Brigham Young University Temperature sensitive multivalent Bordetella avium vaccines
CN113278575B (zh) * 2021-07-13 2021-12-31 南华大学 一种肺炎支原体减毒突变株及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN178995A0 (en) * 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
CN1100871C (zh) * 1999-06-25 2003-02-05 江苏省农业科学院畜牧兽医研究所 猪肺炎支原体克隆致弱株
US6673567B2 (en) * 2000-03-23 2004-01-06 E. I. Du Pont De Nemours And Company Method of determination of gene function
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
CN1612749A (zh) * 2001-07-02 2005-05-04 辉瑞产品公司 用于减弱牲畜体内牛支原体肺炎的猪肺炎支原体疫苗和方法
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
KR20080100384A (ko) * 2006-03-03 2008-11-17 메리얼 리미티드 마이코플라즈마 하이오뉴모니아에 백신
EP2217271B1 (en) * 2007-11-06 2016-05-04 Zoetis Services LLC Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
UA107940C2 (en) * 2009-09-10 2015-03-10 Merial Ltd The vaccine composition that includes the saponin-containing adjuvant
US9324223B2 (en) 2012-06-08 2016-04-26 3M Innovative Properties Company Electronic monitoring home unit and installation methods

Also Published As

Publication number Publication date
EA201190311A1 (ru) 2012-06-29
CA2762587C (en) 2017-11-28
CN102458462B (zh) 2014-03-19
US20120135040A1 (en) 2012-05-31
KR101734590B1 (ko) 2017-05-11
CN102458462A (zh) 2012-05-16
JP5744852B2 (ja) 2015-07-08
AU2010251761B2 (en) 2014-10-09
ES2579935T3 (es) 2016-08-17
EP2453913B1 (en) 2016-06-22
CL2011002923A1 (es) 2012-08-31
BRPI1010679B1 (pt) 2020-09-24
ZA201109185B (en) 2012-09-26
KR20120016282A (ko) 2012-02-23
DK2453913T3 (en) 2016-07-25
CA2762587A1 (en) 2010-11-25
AU2010251761A1 (en) 2011-12-22
WO2010132932A1 (en) 2010-11-25
EP2453913A1 (en) 2012-05-23
EP2453913A4 (en) 2013-10-30
MX2011012362A (es) 2012-04-19
EA021102B1 (ru) 2015-04-30
JP2012527218A (ja) 2012-11-08
BRPI1010679A2 (pt) 2017-07-18
NZ596722A (en) 2013-08-30
US8524252B2 (en) 2013-09-03

Similar Documents

Publication Publication Date Title
PE20120909A1 (es) Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usos de la misma
BR112016006589A2 (pt) composição, e composição de vacina
CL2015001945A1 (es) (divisional de la solicitud n° 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
BRPI0909352A2 (pt) dispositivo terapêutico e que pode ser colocado em contato com um paciente para terapeuticamento resfriar o paciente, sistema para regularizar terapeuticamente a temperatura do corpo de um paciente, método terapêutico para regularizar a temperatura do corpo de um paciente método para terapeuticamente resfriar a temperatura do corpo de um paciente, invólucro, e, envoltório.
BR112014000178A2 (pt) composições tópicas
BR112013031707A2 (pt) fraldas descartáveis
MX362375B (es) Extracto de saliva entera de sanguijuela.
BR112014013786A8 (pt) método para ventilação de um indivíduo, método para rapidamente ventilar um indivíduo que apresenta desconforto respiratório, e, dispositivo para ventilação de um indivíduo através de uma ou mais passagens do corpo
BR112015004875A2 (pt) formulações de anticorpo e seus usos
UY32570A (es) Vacuna viva modificada de mycoplasma bovis mejorada
HK1212249A1 (en) Bioconjugates comprising modified antigens and uses thereof
CL2010001642A1 (es) Composicion farmaceutica topica en gel que comprende a) 0,25 a 4,5% de un agente activo para el tratamiento de la queratosis actinica, b) un agente queratoliticamente activo, c) un formador de gel, d) un solvente organico, y menos de 5% en peso de agua; util para el tratamiento de la queratosis actinica.
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
UY32208A (es) Uso de antigeno de mycoplasma bovis
CL2015001803A1 (es) Composición inmunogénica que comprende cepas del virus del oeste del nilo muerto o inactivado o cualquier antígeno del mismo; y método para disminuir síntomas clínicos asociados a infección por dicho virus en animales (div. sol. n° 445-11)
BR112012020665A2 (pt) artigo depilatório
Brotons et al. Cost of hospitalizing children with invasive pneumococcal pneumonia
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica
Kim et al. A study on occupational satisfaction and stress of visiting nurses at district health centers in Chungnam province
Luo et al. ${\alpha} $-Cyperone Alleviates Lung Cell Injury Caused by Staphylococcus aureus via Attenuation of ${\alpha} $-Hemolysin Expression
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
WO2014030052A3 (en) Compositions comprising an antibody and camostat mesylate (cm)
Deresinski et al. Immunotherapies for Staphylococcus aureus: current challenges and future prospects
BR112015032791A2 (pt) composição para uso como enchimento de cápsula, e, cápsula
Valle et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
FC Refusal